Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations

References

• Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16(11):684–701. doi:https://doi.org/10.1038/s41571-019-0239-8
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Treon SP, Davids MS. Inhibition of the Bruton tyrosine kinase pathway in B-cell lymphoproliferative disorders. Cancer J. 2016;22(1):34–39. doi:https://doi.org/10.1097/PPO.0000000000000170
   PubMed Web of Science ®Google Scholar
• Woyach JA, Bojnik E, Ruppert AS, et al. Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123(8):1207–1213. doi:https://doi.org/10.1182/blood-2013-07-515361
   PubMed Web of Science ®Google Scholar
• Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Publ Gr. 2014;14; doi:https://doi.org/10.1038/nrc3702
   Google Scholar
• Zanwar S, Abeykoon JP, Kapoor P. Current therapeutic options in Waldenström macroglobulinemia. Oncol Hematol Rev. 2019;15(1):39-47. doi:https://doi.org/10.17925/OHR.2019.15.1.39.
   Google Scholar
• Abeykoon JP, Yanamandra U, Kapoor P. New developments in the management of Waldenström macroglobulinemia. Cancer Manag Res. 2017: 9–73. doi:https://doi.org/10.2147/CMAR.S94059
   Google Scholar
• Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307. doi:https://doi.org/10.1182/blood-2018-11-846808
   PubMed Web of Science ®Google Scholar
• Ibrutinib – Annex I summary of product characteristics. [cited July 5, 2019]. https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf
   Google Scholar
• De Weerdt I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629–1639. doi:https://doi.org/10.3324/haematol.2017.164103
   PubMed Web of Science ®Google Scholar
• Orellana-Noia VM, Kluin-Nelemans JC, Williams ME. Front-line therapy in elderly patients with mantle cell lymphoma. Ann Lymphoma. 2019;3:8–8. doi:https://doi.org/10.21037/aol.2019.06.02
   Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(Suppl 5(February)):v78–v84. doi:https://doi.org/10.1093/annonc/mdv303
   PubMedGoogle Scholar
• ESMO Guidelines CommitteeChronic lymphocytic leukaemia treatment recommendations. eUpdate published online 27 June 2017. Ann Oncol. 2017;28(suppl_4):iv149–iv152. doi: https://doi.org/10.1093/annonc/mdx242.
   Google Scholar
• Brown JR. How i treat CLL patients with ibrutinib. Blood. 2018;131(4):379–386. doi:https://doi.org/10.1182/blood-2017-08-764712
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;32(1):23–33. doi:https://doi.org/10.1016/j.annonc.2020.09.019
   PubMed Web of Science ®Google Scholar
• Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835–847. doi:https://doi.org/10.1111/jth.13651
   PubMed Web of Science ®Google Scholar
• Gribben JG, Bosch F, Cymbalista F, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018;180(5):666–679. doi:https://doi.org/10.1111/bjh.15080
   PubMed Web of Science ®Google Scholar
• Thompson PA, Levy V, Tam CS, et al.. The impact of atrial fibrillation on subsequent survival of patients receiving ibrutinib as treatment of chronic lymphocytic leukemia (CLL): an international study 2016;128(22):3242–3242. doi.org/https://doi.org/10.1182/blood.V128.22.3242.3242.
   Google Scholar
• Finnes HD, Chaffee KG, Call TG, et al. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in routine clinical practice HHS public Access author manuscript. Leuk Lymphoma. 2017;58(6):1376–1383. doi:https://doi.org/10.1080/10428194.2016.1251592
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630–1639. doi:https://doi.org/10.1080/10428194.2016.1257795
   PubMed Web of Science ®Google Scholar
• Mato AR, Clasen S, Pickens P, et al. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biol Ther. 2018;19(1):1–2. doi:https://doi.org/10.1080/15384047.2017.1394554
   PubMed Web of Science ®Google Scholar
• Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919–1928. doi:https://doi.org/10.1182/blood.2019000840
   PubMed Web of Science ®Google Scholar
• Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491–1500. doi:https://doi.org/10.1016/j.jacep.2018.06.004
   PubMedGoogle Scholar
• Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–1748. doi:https://doi.org/10.1182/bloodadvances.2017009720
   PubMed Web of Science ®Google Scholar
• Reda G, Fattizzo B, Cassin R, et al. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol. 2018;11(1). doi:https://doi.org/10.1186/s13045-018-0626-0
   Google Scholar
• Baptiste F, Cautela J, Ancedy Y, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Hear. 2019;6(1):1–9. doi:https://doi.org/10.1136/openhrt-2019-001049
   Web of Science ®Google Scholar
• Guha A, Derbala MH, Zhao Q, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72(6):697–698. doi:https://doi.org/10.1016/j.jacc.2018.06.002
   PubMed Web of Science ®Google Scholar
• Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581–2584. doi:https://doi.org/10.1182/blood-2016-10-742437
   PubMed Web of Science ®Google Scholar
• Stühlinger MC, Weltermann A, Staber P, et al. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wien Klin Wochenschr. 2019. doi:https://doi.org/10.1007/s00508-019-1534-1
   Google Scholar
• CHMP. Committee for Medicinal Products for Human Use (CHMP) CHMP Assessment Report; 2014.
   Google Scholar
• Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687–692. doi:https://doi.org/10.1093/cid/ciy175
   PubMed Web of Science ®Google Scholar
• Maffei R, Maccaferri M, Arletti L, et al. Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections. Blood Rev. 2019:100635. doi:https://doi.org/10.1016/j.blre.2019.100635
   Google Scholar
• Morrison V. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma. 2009;9(5):365–370. doi:https://doi.org/10.3816/CLM.2009.n.071
   PubMedGoogle Scholar
• Andrick B, Alwhaibi A, DeRemer DL, et al. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2018;182(5):712–714. doi:https://doi.org/10.1111/bjh.14855
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:https://doi.org/10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Law MF, Ho R, Cheung CKM, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016;22(28):6484–6500. doi:https://doi.org/10.3748/wjg.v22.i28.6484
   PubMed Web of Science ®Google Scholar
• Kreiniz N, Bejar J, Polliack A, et al. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. Hematol Oncol. 2018;36(1):349–354. doi:https://doi.org/10.1002/hon.2387
   PubMed Web of Science ®Google Scholar
• Ahn IE, Jerussi T, Farooqui M, et al. Atypical pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940–1943. doi:https://doi.org/10.1182/blood-2016-06-722991
   PubMed Web of Science ®Google Scholar
• Reinwald M, Silva JT, Mueller NJ, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24:S53–S70. doi:https://doi.org/10.1016/j.cmi.2018.02.009
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European conference on infections in leukemia (ECIL). Leukemia. 2019;33(4):844–862. doi:https://doi.org/10.1038/s41375-019-0388-x
   PubMed Web of Science ®Google Scholar
• La Hoz RM, Morris MI. Intestinal parasites including cryptosporidium, cyclospora, giardia, and microsporidia, entamoeba histolytica, strongyloides, schistosomiasis, and echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Pract. Clin Transplant. 2019;33(9):1–16. doi:https://doi.org/10.1111/ctr.13618
   Web of Science ®Google Scholar
• Fardet L, Généreau T, Poirot J-L, et al. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect. 2007;54(1):18–27. doi:https://doi.org/10.1016/j.jinf.2006.01.016
   PubMed Web of Science ®Google Scholar
• Requena-Méndez A, Buonfrate D, Gomez-Junyent J, et al. Evidence-based guidelines for screening and management of strongyloidiasis in non-endemic countries. Am J Trop Med Hyg. 2017;97(3):645–652. doi:https://doi.org/10.4269/ajtmh.16-0923
   PubMed Web of Science ®Google Scholar
• Silva-Pinto A, Rocha-Pereira N, Andrade J, et al. Protocolo de prevenção de infeções relacionadas com o tratamento de neoplasias hematológicas. Acta Med Port. 2018;31(6):347. doi:https://doi.org/10.20344/amp.10035
   PubMedGoogle Scholar
• Byrd JC, Furman RR, Coutre SE, et al. 2020. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. doi:https://doi.org/10.1158/1078-0432.ccr-19-2856
   Google Scholar
• Rule S, Dreyling MH, Goy A, et al. Long-Term outcomes with ibrutinib versus the prior regimen: A pooled Analysis in relapsed/refractory (R/R) mantle cell Lymphoma (MCL) with up to 7.5 years of extended follow-up. Blood. 2019;134(Supplement_1):1538–1538. doi:https://doi.org/10.1182/blood-2019-124691
   Google Scholar
• Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959. doi:https://doi.org/10.1182/blood-2017-11-818286
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. doi:https://doi.org/10.1056/NEJMoa1812836
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506. doi:https://doi.org/10.1182/blood-2014-10-606038
   PubMed Web of Science ®Google Scholar
• O’Brien S, Hillmen P, Coutre S, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma, Myeloma Leuk. 2018;18(10):648–657.e15. doi:https://doi.org/10.1016/j.clml.2018.06.016
   PubMed Web of Science ®Google Scholar
• Hallek M, Kay NE, Osterborg A, et al. The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/ refractory chronic lymphocytic leukemia. doi:https://doi.org/10.2217/FON.14.119
   Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94. doi:https://doi.org/10.1200/JCO.2012.42.7906
   PubMed Web of Science ®Google Scholar
• Vitale C, Ahn IE, Sivina M, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. 101; 2016. doi:https://doi.org/10.3324/haematol.2015.138289
   Google Scholar
• Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–2615. doi:https://doi.org/10.1182/blood-2016-12-737346
   PubMed Web of Science ®Google Scholar
• Itchaki G, Brown JR. Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. Ther Adv Hematol. 2017;9(1):3–19. doi:https://doi.org/10.1177/2040620717741861
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Quinquenel A, Bijou F, et al. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study. Eur J Cancer. 2020;135:170–172. doi:https://doi.org/10.1016/j.ejca.2020.05.016
   PubMed Web of Science ®Google Scholar
• Silva S, Melo JA, Espada E, et al. Ibrutinib Na vida real: experiencia multicêntrica November Algarve, Portugal Portuguese Society of Hematology Annual Meeting 2017.
   Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879. doi:https://doi.org/10.3324/haematol.2017.182907
   PubMed Web of Science ®Google Scholar
• Winqvist M, Andersson PO, Asklid A, et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematologica. 2019;104(5):e208–e210. doi:https://doi.org/10.3324/haematol.2018.198820
   PubMed Web of Science ®Google Scholar
• Brown JR, Hillmen P, O’Brien S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus Ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2014;124(21):3331–3331. doi:https://doi.org/10.1182/blood.v124.21.3331.3331
   Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi:https://doi.org/10.1056/NEJMoa1509388
   PubMed Web of Science ®Google Scholar
• Iberri DJ, Kwong BY, Stevens LA, et al. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol. 2018;180(1):164–166. doi:https://doi.org/10.1111/bjh.14302
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia. J Oncol Pharm Pract. 2019;25(4):1003–1005. doi:https://doi.org/10.1177/1078155218772327
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;2019. doi:https://doi.org/10.1002/ajh.25638
   Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798. doi:https://doi.org/10.1038/s41375-019-0602-x
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223. doi:https://doi.org/10.1056/NEJMoa1400376
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211. doi:https://doi.org/10.1016/S1470-2045(15)00465-9
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778. doi:https://doi.org/10.1016/S0140-6736(15)00667-4
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program (CTEP). 2017. Common terminology criteria for adverse events (CTCAE).v.5.0[5-7]. Cancer Ther Eval Progr.
   Google Scholar
• Thompson PA, Lévy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–466. doi:https://doi.org/10.1111/bjh.14324
   PubMed Web of Science ®Google Scholar
• Khalid S, Yasar S, Khalid A, et al. Management of atrial fibrillation in patients on ibrutinib: a Cleveland clinic experience. Cureus. 2018. doi:https://doi.org/10.7759/cureus.2701
   Google Scholar
• Vrontikis A, Carey J, Gilreath JA, et al. Proposed algorithm for managing ibrutinib-related atrial fibrillation. Oncology (Williston Park). 2016;30(11):970-4, 980-1, C3.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018;4(11):1553–1568. doi:https://doi.org/10.1001/jamaoncol.2018.2706
   PubMed Web of Science ®Google Scholar
• Roeker LE, Sarraf Yazdy M, Rhodes J, et al. Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia. JAMA Netw Open. 2019;2(12):e1916326. doi:https://doi.org/10.1001/jamanetworkopen.2019.16326
   PubMed Web of Science ®Google Scholar
• Kapelios CJ, Bonou MS, Diamantopoulos P, et al. Ibrutinib-related atrial fibrillation: therapeutic challenges. J Oncol Pharm Pract. 2019;25(5):1258–1260. doi:https://doi.org/10.1177/1078155218785983
   PubMed Web of Science ®Google Scholar
• Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–865. doi:https://doi.org/10.1161/CIRCULATIONAHA.111.060061
   PubMed Web of Science ®Google Scholar
• González-Correa JA, De La Cruz JP. Triflusal: an antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev. 2006;24(1):11–24. doi:https://doi.org/10.1111/j.1527-3466.2006.00011.x
   PubMedGoogle Scholar
• Rogers KA, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019. doi:https://doi.org/10.1038/s41375-019-0481-1
   Google Scholar
• Ball S, Das A, Vutthikraivit W, et al. Risk of infection associated with ibrutinib in patients with B-cell malignancies: A Systematic review and meta-Analysis of Randomized Controlled trials. Clin Lymphoma Myeloma Leuk. 2019. doi:https://doi.org/10.1016/j.clml.2019.10.004
   Google Scholar
• Arthurs B, Wunderle K, Hsu M, et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Reports. 2017;21:27–29. doi:https://doi.org/10.1016/j.rmcr.2017.03.011
   PubMed Web of Science ®Google Scholar
• Tillman BF, Pauff JM, Satyanarayana G, et al. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100(4):325–334. doi:https://doi.org/10.1111/ejh.13020
   PubMed Web of Science ®Google Scholar
• Hsiehchen D, Arasaratnam R, Raj K, et al. Ibrutinib use complicated by progressive multifocal leukoencephalopathy. Oncol. 2018;95(5):319–322. doi:https://doi.org/10.1159/000490617.
   Google Scholar
• EMA. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (CPMP/BPWG/143744/2011 Rev.5). Guideline. 2018: 44. doi:CPMP/BPWG/143744/2011 Rev.1
   Google Scholar
• Narbutas Š, York K, Stein BD, et al. Overview on patient centricity in cancer care. Front Pharmacol. 2017;8(OCT):1–12. doi:https://doi.org/10.3389/fphar.2017.00698
   PubMedGoogle Scholar
• Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 TRIAL. Hematol Oncol. 2019;37:38–40. doi:https://doi.org/10.1002/hon.7_2629
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang X V, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443. doi:https://doi.org/10.1056/nejmoa1817073
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. doi:https://doi.org/10.1016/S1470-2045(18)30788-5
   PubMed Web of Science ®Google Scholar
• Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357–2366. doi:https://doi.org/10.1182/blood-2017-12-820910
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Loscertales J, Terol MJ, et al. Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC study). Clin Lymphoma Myeloma Leuk. 2021. doi:https://doi.org/10.1016/j.clml.2021.07.022
   Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood. 2015;126(6):739–745. doi:https://doi.org/10.1182/blood-2015-03-635326
   PubMed Web of Science ®Google Scholar
• Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799–1803. doi:https://doi.org/10.1038/s41375-018-0023-2
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 Trial of Ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410. doi:https://doi.org/10.1056/nejmoa1802917
   PubMed Web of Science ®Google Scholar
• Treon SP, Meid K, Gustine J, et al. Long-Term follow-Up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2021;39(6):565–575. doi:https://doi.org/10.1200/JCO.20.00555
   PubMed Web of Science ®Google Scholar